| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
ACHP targets IκB kinase (IKK), specifically the IKKα and IKKβ isoforms. It acts as a selective and orally active IκB kinase inhibitor. ACHP has IC50 values of 8.5 nM for IKKβ and 250 nM for IKKα. By inhibiting IKK, ACHP prevents the phosphorylation and degradation of IκB, thereby blocking the nuclear translocation of NF-κB and inhibiting NF-κB-mediated gene expression.
|
|---|---|
| ln Vitro |
In vitro, ACHP is a selective IKK inhibitor with IC50 values of 8.5 nM for IKKβ and 250 nM for IKKα. It inhibits the DNA binding activity of NF-κB, blocks the NF-κB pathway in multiple myeloma cell lines, and induces cell growth arrest and apoptosis. ACHP also has anti-HIV-1 activity by inhibiting HIV-1 LTR-driven gene expression.
|
| ln Vivo |
In vivo, ACHP (0.3, 1, 3 mg/kg; p.o.; single) exhibits anti-inflammatory activity in arachidonic acid-induced ear edema mice model. The compound is orally active. Its ability to inhibit NF-κB activation suggests potential applications in inflammatory diseases and cancer.
|
| Enzyme Assay |
The in vitro enzyme assay for ACHP involves measuring the inhibition of IKKα and IKKβ kinase activity. Recombinant IKK kinases are incubated with a substrate (e.g., IκBα) and ATP in the presence of varying compound concentrations. The IC50 values of 8.5 nM for IKKβ and 250 nM for IKKα are determined by quantifying the reduction in substrate phosphorylation.
|
| Cell Assay |
Cellular assays for ACHP are performed using multiple myeloma cell lines or other NF-κB-dependent cells. Cells are treated with ACHP at various concentrations. NF-κB DNA binding activity is assessed by electrophoretic mobility shift assay (EMSA) or ELISA. Cell proliferation and apoptosis are measured using standard assays. HIV-1 LTR-driven gene expression is assessed using reporter assays.
|
| Animal Protocol |
In vivo animal studies for ACHP are conducted in arachidonic acid-induced ear edema mice model. ACHP is administered orally at 0.3, 1, or 3 mg/kg. Anti-inflammatory activity is assessed by measuring ear edema reduction.
|
| ADME/Pharmacokinetics |
ACHP is an orally active compound. It has a molecular weight of 364.44 g/mol and a molecular formula of C21H24N4O2. The compound is soluble in DMSO. Specific PK parameters such as half-life, bioavailability, and clearance have not been detailed in the available sources.
|
| Toxicity/Toxicokinetics |
Toxicity data for ACHP are not reported in the available sources. As a research compound, it is not intended for therapeutic use. The compound has been evaluated in animal models at doses up to 3 mg/kg. Specific toxicological profiles have not been characterized.
|
| References |
|
| Additional Infomation |
2-Amino-6-[2-(cyclopropylmethoxy)-6-oxo-1-cyclohex-2,4-dienemethylene]-4-(4-piperidinyl)-1H-pyridine-3-nitrile is a member of the quinone methane family.
ACHP is a research compound for studying IKK/NF-κB signaling in cancer, inflammation, and HIV-1 infection. It is a selective IKK inhibitor with IC50 values of 8.5 nM for IKKβ and 250 nM for IKKα. The compound is orally active and induces cancer cell cycle arrest and apoptosis. It is available from commercial suppliers for research use only. |
| Molecular Formula |
C21H24N4O2
|
|---|---|
| Molecular Weight |
364.4409
|
| Exact Mass |
364.19
|
| Elemental Analysis |
C, 69.21; H, 6.64; N, 15.37; O, 8.78
|
| CAS # |
406208-42-2
|
| PubChem CID |
135465539
|
| Appearance |
Solid powder
|
| LogP |
3.422
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
540
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C1=C([H])C([H])=C([H])C(=C1C1C([H])=C(C(C#N)=C(N([H])[H])N=1)C1([H])C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])O[H])C([H])([H])C1([H])C([H])([H])C1([H])[H]
|
| InChi Key |
DYVFBWXIOCLHPP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H24N4O2/c22-11-16-15(14-6-8-24-9-7-14)10-17(25-21(16)23)20-18(26)2-1-3-19(20)27-12-13-4-5-13/h1-3,10,13-14,24,26H,4-9,12H2,(H2,23,25)
|
| Chemical Name |
2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-ylpyridine-3-carbonitrile
|
| Synonyms |
ACHP
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7439 mL | 13.7197 mL | 27.4394 mL | |
| 5 mM | 0.5488 mL | 2.7439 mL | 5.4879 mL | |
| 10 mM | 0.2744 mL | 1.3720 mL | 2.7439 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
